Treatment of Parkinson's disease should begin with a dopamine agonist
- 1 September 1999
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 14 (5) , 725-730
- https://doi.org/10.1002/1531-8257(199909)14:5<725::aid-mds1003>3.0.co;2-l
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Ropinirole for the Treatment of Early Parkinson Disease: A 12-Month ExperienceArchives of Neurology, 1998
- Costs of drug treatment in Parkinson's diseaseMovement Disorders, 1998
- Cost Effectiveness of Pramipexole in Parkinson??s Disease in the USPharmacoEconomics, 1998
- The Economic Impact of Parkinson???s DiseasePharmacoEconomics, 1998
- Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor ComplicationsDrugs, 1998
- Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- Neuroprotection in Parkinson's DiseaseThe Lancet, 1996
- New Directions in the Drug Treatment of Parkinson??s DiseaseDrugs & Aging, 1996
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Current Status of Dopamine Agonists in Parkinson??s Disease ManagementDrugs, 1993